InvestorsHub Logo
Post# of 1029
Next 10
Followers 229
Posts 21457
Boards Moderated 2
Alias Born 08/03/2006

Re: turning stone post# 863

Wednesday, 10/02/2019 1:55:23 PM

Wednesday, October 02, 2019 1:55:23 PM

Post# of 1029
We've got an excellent team leading the way.


DURECT commissioned the advisory services of Dr. Lee S. Simon to lead the Company's preparation efforts to prepare for the advisory committee meeting. Dr. Simon is a physician and research scientist who served as the FDA's Division Director of Analgesic, Anti-inflammatory and Ophthalmologic Drug Products from 2001 to 2003, and is now a Principal at SDG, LLC, an FDA advisory firm.

"We look forward to a productive discussion with the advisory committee," stated James E. Brown, President and CEO of DURECT. "If approved, we believe that POSIMIR could help address an important need for new long-acting, non-opioid pain products in the post-operative pain setting."

Pleased to have been able to add a bit this morning.

"Perfection is not attainable, but if we chase perfection we can catch
excellence." Vince Lombardi
Do your research! Play the TA. All posts are my opinion.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent DRRX News